Merck gets US FDA nod for first-in-its-class oral cholesterol drug
Merck has achieved a regulatory milestone with the FDA approval of Lipfendra, the first-of-its-kind oral treatment for reducing cholesterol.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The United States Food and Drug Administration has granted approval to Merck for a new medication known as Lipfendra. This drug represents a significant pharmaceutical development as it is the world's first oral PCSK9 treatment designed to reduce cholesterol. According to reports from WFLA, the medication is specifically indicated for use in patients who are considered high-risk. This approval allows for a pill-based administration of a treatment class that previously lacked an oral delivery method, marking a first-of-its-kind entry into the medical market for cholesterol management. Coverage of this regulatory win is highlighted across multiple news outlets, including Fierce Pharma, which explicitly identifies the drug by its name, Lipfendra, and notes that Merck has scored a victory at the FDA.
Other reports, such as those from ABC7 Los Angeles, emphasize the nature of the drug as a first-of-its-kind pill intended to lower cholesterol levels. These outlets collectively focus on the transition of PCSK9 treatments into an oral format, shifting the delivery method from previous iterations of this class of cholesterol-reducing medication to a more accessible pill form. To understand the significance of this event, it is necessary to recognize that Lipfendra is the first oral treatment in the PCSK9 class of drugs. The FDA's approval means that high-risk patients now have a new tool for cholesterol reduction that does not rely on the previous delivery mechanisms associated with PCSK9 inhibitors. The development of an oral pill for this specific medical purpose is characterized in the reporting as a first-in-its-class achievement for Merck, expanding the options available for patients who require aggressive cholesterol management to mitigate health risks.
Looking ahead, the focus remains on the deployment of Lipfendra following its FDA nod. While the coverage establishes the approval and the target demographic of high-risk patients, further details regarding the specific rollout or pricing are not yet specified in the current reports. Observers will be monitoring how the introduction of the world's first oral PCSK9 treatment affects the broader landscape of cholesterol medication and how Merck implements the distribution of this new pill to the high-risk patient populations mentioned by WFLA.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 111d ago.
Quick answers
What is the name of the new cholesterol drug approved by the FDA?
The drug is called Lipfendra.
Which company developed Lipfendra?
The drug was developed by Merck.
What makes Lipfendra unique compared to other PCSK9 treatments?
Lipfendra is the world's first oral treatment in the PCSK9 class, meaning it is delivered as a pill.
Coverage (3)
- FDA approves 1st-of-its-kind pill to reduce cholesterol ABC7 Los Angeles · 123d ago
- FDA approves first-of-its-kind pill to cut cholesterol in high-risk patients WFLA · 124d ago
- Merck scores at FDA as Lipfendra becomes world's first oral PCSK9 treatment Fierce Pharma · 124d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche secures United States Food and Drug Administration approval for its new oral breast-cancer pill, Wilserdly.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
Two-drug therapy reduces heart artery plaque more than statins alone
New clinical study findings reveal conflicting evidence regarding the efficacy of combining statins with ezetimibe.